IRIS
BRAVACCINI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.931
AS - Asia 1.020
EU - Europa 707
SA - Sud America 335
AF - Africa 18
OC - Oceania 2
Totale 4.013
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.889
SG - Singapore 475
HK - Hong Kong 390
BR - Brasile 313
IE - Irlanda 311
IT - Italia 89
DE - Germania 88
TR - Turchia 54
FR - Francia 41
NL - Olanda 32
GB - Regno Unito 30
FI - Finlandia 26
CA - Canada 24
IN - India 21
RU - Federazione Russa 20
BD - Bangladesh 19
VN - Vietnam 16
MX - Messico 15
AT - Austria 14
IQ - Iraq 12
LT - Lituania 11
AR - Argentina 8
ES - Italia 8
PL - Polonia 7
ZA - Sudafrica 7
BE - Belgio 6
CZ - Repubblica Ceca 6
TN - Tunisia 6
UZ - Uzbekistan 6
CN - Cina 5
CO - Colombia 5
JP - Giappone 5
SA - Arabia Saudita 5
SE - Svezia 5
UA - Ucraina 5
PK - Pakistan 4
VE - Venezuela 4
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
EC - Ecuador 2
KG - Kirghizistan 2
PY - Paraguay 2
RS - Serbia 2
SN - Senegal 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
JO - Giordania 1
KE - Kenya 1
MA - Marocco 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 4.013
Salva come PNG Salva come JPEG
Città #
Dallas 1.225
Hong Kong 388
Dublin 311
Singapore 203
Santa Clara 138
Boardman 131
The Dalles 88
Istanbul 43
Munich 38
Ashburn 36
Assago 32
São Paulo 30
Amsterdam 23
Helsinki 23
Los Angeles 18
Frankfurt am Main 16
Boston 10
Chicago 10
Milan 10
Vienna 10
Belo Horizonte 9
Düsseldorf 9
Montreal 9
New York 9
San Francisco 9
Brasília 8
Rio de Janeiro 8
Brooklyn 7
Ho Chi Minh City 7
Ankara 6
Brno 6
Brussels 6
Campinas 6
Mexico City 6
Paris 6
Toronto 6
Atlanta 5
Bexley 5
Chennai 5
Lugo 5
Stockholm 5
Tashkent 5
Tokyo 5
Warsaw 5
Bogotá 4
Guarulhos 4
Juiz de Fora 4
Manchester 4
New Delhi 4
Nuremberg 4
Ottawa 4
Porto Alegre 4
Riyadh 4
Rome 4
Betim 3
Birmingham 3
Denver 3
Houston 3
Johannesburg 3
Lauterbourg 3
Limeira 3
London 3
Maricá 3
Milwaukee 3
Palhoça 3
Pescara 3
Portsmouth 3
Ribeirão Preto 3
Roubaix 3
Salvador 3
Santo André 3
São Sebastião do Paraíso 3
Turku 3
Viamão 3
Virginia Beach 3
Americana 2
Apodi 2
Asunción 2
Atibaia 2
Avaré 2
Baku 2
Basra 2
Belgrade 2
Bishkek 2
Cape Town 2
Caxias do Sul 2
Charlotte 2
Cincinnati 2
Contagem 2
Curitiba 2
Dakar 2
Delhi 2
Fortaleza 2
Garanhuns 2
Hortolândia 2
Itajubá 2
Itapema 2
Itaquaquecetuba 2
João Pessoa 2
La Marsa 2
Totale 3.093
Salva come PNG Salva come JPEG
Nome #
The current status of biomarkers for bladder cancer: progress and challenges 136
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 77
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. 65
Biomarkers: which ones do we really need today? 63
The use of platelets as a clinical tool in oncology: opportunities and challenges 54
Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer 52
Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study 49
Expanding the Horizon of Multidisciplinarity: Incorporating Biomechanical, Metabolic, and Functional Factors Into Registry-Based Research to Predict Subsequent Risk for Total Knee Arthroplasty 45
A functional survey of the regulatory landscape of estrogen-receptor-positive breast cancer evolution 44
Androgen receptor signaling pathways as a target for breast cancer treatment 43
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors 43
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 41
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 40
Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment? 40
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota 39
Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension 38
Are we ready to use TMB in breast cancer clinical practice? 37
Urinary Biomarkers in Tumors: An Overview 37
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 36
Evaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa 36
An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection 36
Letter to the Editor discussing: Hacker S, Lenz C, Reichert L, Ringseis R, Zentgraf K, Krüger K. Vitamin D status and its determinants in German elite athletes. Eur J Appl Physiol. 2025 Jan 4. doi: 10.1007/s00421-024–05699-6 36
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in patients with different subtypes of breast cancer 36
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma insitu treated with surgery and radiotherapy 36
Telomerase Activity Analysis In Urine Sediment for Bladder Cancer 36
An H-1 NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 36
TMB in NSCLC: A Broken Dream? 35
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 35
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 35
Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance 35
Androgen receptor in breast cancer: The "5W" questions 35
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 34
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 34
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients 34
Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study 34
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 34
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 34
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity 33
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 33
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design 33
ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA 33
Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential 33
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial 32
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 32
Usefulness of immunological detection of the human telomerase reverse transcriptase 32
Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer 32
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells 31
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer 31
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit) 31
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 30
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data 30
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 30
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 30
Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR) 29
Expanding Roles of De Novo Lipogenesis in Breast Cancer 29
Relevance of urine telomerase in the diagnosis of bladder cancer 29
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer 29
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer 29
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 29
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? 28
What to look for in cell-free DNA from breast cancer patients 28
In-111-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance 28
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 28
Why the complications of COVID-19 patients differ in elderly and young cancer patients 28
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer? 28
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer 27
Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa 27
Combined analysis of miR-200 family and its significance for breast cancer 27
Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro 27
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression 27
Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer" 27
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 27
Urine telomerase: An important marker in the diagnosis of bladder cancer 26
International consensus on severe lung cancer-the first edition 26
CAR T cells targeting options in the fight against multiple myeloma 26
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. 26
Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold 26
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis 25
Spotlight on PSMA as a new theranostic biomarker for bladder cancer 25
The current role of telomerase in the diagnosis of bladder cancer 25
Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients 25
Biofunctional characteristics of in situ and invasive breast carcinoma 25
No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country 25
Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue 25
Unraveling the protein kinase C/NDRG1 signaling network in breast cancer. 25
Urine telomerase activity for the detection of bladder cancer in females 25
Sorafenib for the treatment of breast cancer 25
Erratum to: Benefit from anthracyclines in relation to biological profiles in early breast cancer 25
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 24
Role of Telomerase in Cervical Lesions as Prognostic Marker: A Comparison Between Immunohistochemistry and Fluorescence In Situ Hybridization 24
Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR) 24
Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients 24
FAP inhibitors: are we really using the best method to evaluate the residence time? 24
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 24
The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study 24
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls 23
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer A case report 23
Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling 23
Molecular characterization of cytotoxic and drug resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines 23
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinomain situ 23
Totale 3.335
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024187 0 0 0 0 0 0 0 0 0 0 0 187
2024/20252.496 264 71 193 57 234 318 149 135 304 299 283 189
2025/20261.587 313 965 309 0 0 0 0 0 0 0 0 0
Totale 4.270